Refanezumab(Refanezumab) - 药物靶点：MAG_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti-MAG monoclonal antibody

+ [1]

靶点

MAG

作用机制

MAG抑制剂(髓磷脂相关糖蛋白抑制剂)

治疗领域

神经系统疾病心血管疾病

在研适应症-

非在研适应症

短暂性脑缺血发作缺血性卒中脑卒中

原研机构

GSK Plc

在研机构-

非在研机构

GSK Plc

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 319372583H

来源: *****

Sequence Code 17117615L

来源: *****

关联

9

项与 Refanezumab 相关的临床试验

NCT01808261 / Terminated临床2期

Study MAG104615, a Proof of Concept Study for GSK249320 Versus Placebo in Stroke Patients

Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients.

开始日期2013-05-18

申办/合作机构

GSK Plc

EUCTR2012-004494-23-DE / Not yet recruitingN/A

Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients

开始日期2013-04-09

申办/合作机构

GlaxoSmithKline Research & Development Ltd.

EUCTR2010-024087-17-CZ / Not yet recruitingN/A

Study MAG104615, a Proof of Concept Study for GSK249320versus placebo in Stroke Patients - POC in patients with ischaemic stroke

开始日期2011-12-20

申办/合作机构

GlaxoSmithKline Research & Development Ltd.

100 项与 Refanezumab 相关的临床结果

登录后查看更多信息

100 项与 Refanezumab 相关的转化医学

登录后查看更多信息

100 项与 Refanezumab 相关的专利（医药）

登录后查看更多信息

86

项与 Refanezumab 相关的文献（医药）

2024-01-01·British Journal of Haematology

Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia

Article

作者: Gupta, Rajeev ; Vos, Josephine M I ; Patel, Aisha ; Kwakernaak, Arjan J ; D'Sa, Shirley ; Japzon, Nicole ; Kyriakou, Charalampia ; Wechalekar, Ashutosh D ; Khwaja, Jahanzaib ; Rismani, Ali ; Pluimers, Tessa E ; Salter, Simon

SummaryMonoclonal immunoglobulin M‐associated type I cryoglobulinaemia is poorly characterised. We screened 534 patients with monoclonal IgM disorders over a 9‐year period and identified 134 patients with IgM type I cryoglobulins. Of these, 76% had Waldenström macroglobulinaemia (WM), 5% had other non‐Hodgkin lymphoma (NHL) and 19% had IgM monoclonal gammopathy of undetermined significance (MGUS). Clinically relevant IgM‐associated disorders (including cold agglutinin disease [CAD], anti‐MAG antibodies, amyloidosis and Schnitzler syndrome) coexisted in 31%, more frequently in MGUS versus WM/NHL (72% vs. 22%/29%, p < 0.001). The majority of those with cryoglobulins and coexistent CAD/syndrome had the molecular characteristics of a CAD clone (wild‐type MYD88 in 80%). A half of all patients had active manifestations at cryoglobulin detection: vasomotor (22%), cutaneous (16%), peripheral neuropathy (22%) and hyperviscosity (9%). 16/134 required treatment for cryoglobulin‐related symptoms alone at a median of 38 days (range: 6–239) from cryoglobulin detection. At a median follow‐up of 3 years (range: 0–10), 3‐year cryoglobulinaemia‐treatment‐free survival was 77% (95% CI: 68%–84%). Age was the only predictor of overall survival. Predictors of cryoglobulinaemia‐related treatment/death were hyperviscosity (HR: 73.01; 95% CI: 15.62–341.36, p < 0.0001) and cutaneous involvement (HR: 2.95; 95% CI: 1.13–7.71, p = 0.028). Type I IgM cryoglobulinaemia is more prevalent than previously described in IgM gammopathy and should be actively sought.

2023-02-01·European Journal of Neurology2区 · 医学

A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody

2区 · 医学

Article

作者: Bianchi, Elisa ; Marfia, Girola A. ; Cocito, Dario ; Giannotta, Claudia ; Doneddu, Pietro E. ; Briani, Chiara ; Cosentino, Giuseppe ; Ruiz, Marta ; Nobile‐Orazio, Eduardo ; Benedetti, Luana ; Filosto, Massimiliano ; Liberatore, Giuseppe ; Manganelli, Fiore

AbstractBackground and purposeA diagnostic score was developed to discriminate anti‐myelin‐associated‐glycoprotein (MAG) neuropathy from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and applied it to patients with atypical anti‐MAG neuropathy.MethodsThe clinical and electrophysiological features of patients with a diagnosis of typical anti‐MAG neuropathy were compared to those of patients with a diagnosis of CIDP. The association of each feature with the diagnosis was assessed in the two groups. Features showing a significant association with the diagnosis were included in a multivariable logistic regression model and adjusted odds ratios were estimated for each feature. A score ranging from 1 to 3 was applied to each feature based on the magnitude of the estimated odds ratios. The score was then applied to patients with a clinical diagnosis of CIDP who also had high anti‐MAG antibody titers (CIDP‐MAG).ResultsThirty‐one anti‐MAG neuropathy patients, 45 typical CIDP patients and 16 CIDP‐MAG patients were included. Scores in anti‐MAG antibody patients ranged from 1 to 5 and in CIDP patients from −7 to −1. Using the score, 4/16 CIDP‐MAG patients were diagnosed to have anti‐MAG neuropathy and 12/16 patients to have CIDP. Response to intravenous immunoglobulin in the CIDP‐MAG patients classified as CIDP was similar to that of definite CIDP patients and higher than that of anti‐MAG neuropathy patients.ConclusionsOur score allowed an accurate discrimination to be made, amongst patients with anti‐MAG antibodies, of those affected by CIDP and the patients with anti‐MAG neuropathy. This score may help proper treatment to be chosen for patients with anti‐MAG antibodies with a CIDP‐like presentation.

2023-01-01·Revue Neurologique

Entrapment partly participates in the longitudinal progression of neuropathy with anti-MAG antibodies

Article

作者: Kanouchi, T ; Yokota, T ; Ohara, M ; Sanjo, N

Neuropathy with anti-myelin-associated glycoprotein (MAG) antibodies commonly demonstrates distal-dominant prolongation of nerve conduction. However, recent electrophysiological studies have shown that distal motor demyelination is not always a distinct feature. We aimed to elucidate whether the longitudinal progression of nerve impairment occurs in a distal-dominant manner. Seven patients with neuropathy with anti-MAG antibodies were enrolled. Sequential nerve conduction studies revealed nerve conduction reduction only at the wrist segment in the median nerve of the patients, but not in the ulnar nerve. Median nerve entrapment at the wrist may play a role in longitudinal disease progression in neuropathy with anti-MAG antibodies.

100 项与 Refanezumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Refanezumab	-	DB14908

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
缺血性卒中	临床2期	德国	GSK Plc	2013-05-18
缺血性卒中	临床2期	英国	GSK Plc	2013-05-18
缺血性卒中	临床2期	美国	GSK Plc	2013-05-18
缺血性卒中	临床2期	加拿大	GSK Plc	2013-05-18
短暂性脑缺血发作	临床2期	德国	GSK Plc	2009-07-08
短暂性脑缺血发作	临床2期	加拿大	GSK Plc	2009-07-08
短暂性脑缺血发作	临床2期	美国	GSK Plc	2009-07-08
脑卒中	临床2期	德国	GSK Plc	2009-07-08
脑卒中	临床2期	美国	GSK Plc	2009-07-08
脑卒中	药物发现	加拿大	GSK Plc	2009-07-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00833989 (MAG111539, CTgov)	临床2期	脑卒中 \| 短暂性脑缺血发作	42	PLACEBO	選夢齋艱壓窪餘顧醖構(壓範鑰衊糧鬱壓繭構範) = 夢醖衊餘夢艱艱獵鹹蓋選鹹鹹築簾鑰壓夢糧壓 (鏇網糧壓築衊蓋簾遞壓, 餘餘鏇衊壓醖餘鬱構遞 ~ 憲獵糧餘壓網蓋艱鹽網) 更多	-	2017-10-16
NCT01808261 (104615, CTgov)	临床2期	缺血性卒中	134	Placebo	鑰蓋構鏇膚廠醖餘網壓(鏇齋齋構鏇淵製鹹選鏇) = 構膚鏇積壓鑰積顧淵網壓繭遞觸積製積廠鏇鹹 (築鹽憲膚選鑰選憲構築, 鑰衊獵糧壓網廠選遞顧 ~ 齋鏇膚網淵鹽鑰淵淵遞) 更多	-	2017-10-03
AAN2013	N/A	脑卒中 myelin-associated glycoprotein (MAG) \| S100β	42	GSK249320 1 mg/kg	廠網選餘憲齋築餘鏇衊(選壓顧積壓製淵艱積廠) = 壓鹹憲淵網廠鹹繭選獵顧糧構積淵願繭夢餘構 (淵鏇膚簾憲齋淵製鬱顧 ) 更多	积极	2013-02-12
AAN2013	N/A	脑卒中 myelin-associated glycoprotein (MAG) \| S100β	42	GSK249320 5 mg/kg	廠網選餘憲齋築餘鏇衊(選壓顧積壓製淵艱積廠) = 蓋鬱醖廠窪顧糧餘鬱繭顧糧構積淵願繭夢餘構 (淵鏇膚簾憲齋淵製鬱顧 ) 更多	积极	2013-02-12
NCT00622609 (Pubmed \| Clin Pharmacol Ther)	临床1期	-	47	GSK249320	(網鬱窪夢簾願顧齋簾範) = showing dose linearity 餘選獵鹹蓋蓋窪膚鹹襯 (壓糧積鏇膚窪壓顧蓋鬱 )	-	2013-02-01